Last edition
News about Market
Aptus Pharma plans its next growth phase with a INR 44.88 crore preferential equity issue, focusing on manufacturing, pan-India expansion and global markets.
Market | 24/08/2026 | By News Bureau
Glenmark Launches Calcium Gluconate Injection in US
Glenmark launches Calcium Gluconate Injection USP in the US, offering a bioequivalent and therapeutically equivalent alternative to Fresenius Kabi’s reference drug.
Market | 21/08/2026 | By News Bureau
Mankind Pharma In-Licenses Two Insulin Analogues from China for Indian Market
Mankind Pharma has signed an exclusive in-licensing and marketing agreement with China-based Chongqing Chenan Biopharmaceutical for Insulin Degludec and Insulin Degludec plus Aspart combination in India, strengthening its injectable diabetes portfolio.
Market | 20/08/2026 | By News Bureau
Symbiotec Pharmalab to Open IPO for Subscription on August 24, 2026
Symbiotec Pharmalab will open its IPO for subscription from August 24–27, 2026, with a price band of INR 938–INR 988 per share and an OFS component of up to INR 1,607 crore.
Market | 20/08/2026 | By News Bureau | 108
Glenmark Pharmaceuticals Receives US FDA Approval for Fluticasone Propionate Nasal Spray
Glenmark Pharmaceuticals receives US Food and Drug Administration (FDA) approval for Fluticasone Propionate Nasal Spray, a bioequivalent and therapeutically equivalent generic of Flonase Nasal Spray.
Market | 20/08/2026 | By News Bureau
Lupin and Tenpoint Therapeutics Announce Strategic Partnership to Commercialise YUVEZZI in Europe
Lupin and Tenpoint Therapeutics partner to commercialise YUVEZZI in the European Union (EU), The UK, Switzerland, Norway, and Iceland and expand access to the once-daily dual-agent eye drop for presbyopia.
Market | 20/08/2026 | By News Bureau
BioMarin to Acquire Alesta Therapeutics for Oral Hypophosphatasia Therapy ALE1
BioMarin will acquire Alesta Therapeutics for USD 275 million upfront, gaining ALE1, a potential first oral therapy for hypophosphatasia, plus milestone payments.
Market | 20/08/2026 | By News Bureau
Roche Canada Completes pCPA Negotiations for Perjeta in Early HER2-Positive Breast Cancer
Roche Canada has completed pCPA negotiations for Perjeta in combination with trastuzumab and chemotherapy for eligible patients with HER2-positive early-stage breast cancer, bringing the treatment closer to potential public reimbursement across Canada.
Market | 20/08/2026 | By News Bureau
LEO Pharma has agreed to acquire worldwide rights to Tanabe Pharma’s oral MC1R agonist dersimelagon for up to USD 435 million in upfront and near-term milestones, strengthening its rare dermatology pipeline for EPP and XLP.
Market | 19/08/2026 | By News Bureau
Sandoz and Henlius Partner on up to 10 Biosimilars
Sandoz partners with Henlius on up to 10 biosimilars, expanding its pipeline to 39 assets with potential to reach 46, including cetuximab, evolocumab and belimumab.
Market | 19/08/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy